Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 8/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434918 | 1.00 | SCN9A (0.32) | SCN9ADPP4DPP7RORCSLC18A3 | |
| SCHEMBL20973259 | 1.00 | SCN9A (0.32) | SCN9ADPP4DPP7RORCSLC18A3 | |
| SCHEMBL22467822 | 1.00 | SCN9A (0.32) | SCN9ADPP4DPP7RORCSLC18A3 | |
| SCHEMBL17801581 | 1.00 | SCN9A (0.32) | SCN9ADPP4DPP7RORCSLC18A3 | |
| SCHEMBL1964520 | 0.85 | L3MBTL3 (0.31) | L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL2223995 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 | |
| SCHEMBL288363 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 | |
| SCHEMBL2221226 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 | |
| SCHEMBL1444883 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 | |
| SCHEMBL2221215 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111527091-B | Oxy-fluoropiperidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2023-03-28 | — | — | CN | disclosed |
| CN-111527091-A | Oxy-fluoropiperidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2020-08-11 | — | — | CN | disclosed |
| EP-3227279-B1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | LILLY CO ELI (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3227279-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | Eli Lilly and Company (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9776992-B2 | 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170233378-A1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016089670-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2016-06-09 | — | — | WO | disclosed |
| CN-102089307-A | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2011-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233378-A1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | CDKN1A, API5, NUTF2 | SCN9A 4226/4885DPP4 1338/4885DPP7 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.